Meeting
2022 ASCO Genitourinary Cancers Symposium
Disease progression and competing mortality for men undergoing active surveillance for low-risk prostate cancer.
Authors
Kripa Guram
VA San Diego Healthcare System, San Diego, CA
Kripa Guram , Tyler J. Nelson , Rishi Deka , Michael Vincent Sherer , Gustavo Rodrigues De Moraes , Brent S. Rose
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Other
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 282)
DOI
10.1200/JCO.2022.40.6_suppl.282
Abstract #
282
Poster Bd #
M11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Men with adrenal-permissive HSD3B1 genotype and prostate cancer mortality: Results from the Veterans Affairs Health System Million Veteran Program.
First Author: Rana R. McKay
Poster
2021 Genitourinary Cancers Symposium
PSA velocity to predict clinical progression in African American and non-Hispanic White patients with low-risk prostate cancer undergoing active surveillance.
First Author: Juan Javier-Desloges
Poster
2013 Genitourinary Cancers Symposium
Relationship of overall survival and the frequency of performing transrectal ultrasound-guided biopsy of the prostate in those patients with low-risk tumors electing active surveillance.
First Author: David D. Buethe
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.
First Author: Lauren Lenz